LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 273

Search options

  1. Book: A review of the clinical pharmacology of Maraviroc

    Boffito, Marta

    (British journal of clinical pharmacology ; 65, Suppl. 1)

    2008  

    Author's details guest ed. Marta Boffito
    Series title British journal of clinical pharmacology ; 65, Suppl. 1
    Collection
    Language English
    Size 106 S. : graph. Darst.
    Publisher Blackwell
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT015494844
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 1118 -65,Suppl.1- not available for loan Zeitschriften-Lesesaal

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Update on injectable antiretrovirals at HIV Glasgow.

    Waters, Laura / Boffito, Marta

    The lancet. HIV

    2023  Volume 10, Issue 2, Page(s) e75–e77

    MeSH term(s) Humans ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Anti-Retroviral Agents/therapeutic use ; Anti-HIV Agents/therapeutic use
    Chemical Substances Anti-Retroviral Agents ; Anti-HIV Agents
    Language English
    Publishing date 2023-01-05
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2352-3018
    ISSN (online) 2352-3018
    DOI 10.1016/S2352-3018(22)00372-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: A case report highlighting drug-drug interactions between 3 life-saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs.

    Suchak, Tara / Bracchi, Margherita / Mercer, Maria / Lander, Frances / Boffito, Marta

    British journal of clinical pharmacology

    2024  

    Abstract: We here present a case providing valuable insights for clinicians who deliver care to patients identifying as transgender or nonbinary. A 30-year-old trans woman presented to sexual health services requesting a routine sexual health screen and was ... ...

    Abstract We here present a case providing valuable insights for clinicians who deliver care to patients identifying as transgender or nonbinary. A 30-year-old trans woman presented to sexual health services requesting a routine sexual health screen and was subsequently diagnosed with HIV and syphilis. She started antiretrovirals for HIV (bictegravir/tenoforvir alafenamide/emtricitabine) 12 days later and was treated with benzathine penicillin G. The patient also had a positive tuberculosis (TB) ELIspot blood test result and further investigations proved the presence of active TB in the chest with mediastinal involvement. She commenced treatment for TB with quadruple therapy, including rifampicin. Due to the clinically significant interaction between rifampicin and bictegravir, the patient's antiretroviral treatment was switched to dolutegravir 50 mg twice daily in combination with tenofovir disoproxil fumarate and emtricitabine. As the patient had transitioned from male to female and was self-medicating with oestrogen-containing feminizing hormone therapy, her hormonal treatment was optimized and blood levels of oestradiol were closely monitored and titrated to manage the drug-drug interaction between rifampicin and oestrogen to ensure the latter would be maintained within the expected therapeutic range. Our case report demonstrates the importance of combining treatment of multiple conditions under 1 team ideally integrated with gender services to prevent multiple attendances and mismanagement of feminizing hormone therapies.
    Language English
    Publishing date 2024-04-10
    Publishing country England
    Document type Case Reports
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.16064
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1118: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: More evidence for worse COVID-19 outcomes in people with HIV.

    Boffito, Marta / Waters, Laura

    The lancet. HIV

    2021  Volume 8, Issue 11, Page(s) e661–e662

    MeSH term(s) COVID-19 ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; Humans ; SARS-CoV-2
    Language English
    Publishing date 2021-10-13
    Publishing country Netherlands
    Document type Journal Article ; Comment
    ISSN 2352-3018
    ISSN (online) 2352-3018
    DOI 10.1016/S2352-3018(21)00272-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Editorial: Is it time to implement injectable antiretroviral treatments globally?

    Boffito, Marta / Scarsi, Kim / Orkin, Chloe

    Current opinion in HIV and AIDS

    2022  Volume 17, Issue 3, Page(s) 119–120

    Language English
    Publishing date 2022-04-20
    Publishing country United States
    Document type Editorial
    ZDB-ID 2502511-9
    ISSN 1746-6318 ; 1746-630X
    ISSN (online) 1746-6318
    ISSN 1746-630X
    DOI 10.1097/COH.0000000000000736
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6812: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV.

    Waters, Laura / Mehta, Viraj / Gogtay, Jaideep / Boffito, Marta

    Journal of virus eradication

    2021  Volume 7, Issue 1, Page(s) 100028

    Abstract: This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3 ​TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen. Key trials that assess the relative efficacy, ... ...

    Abstract This article evaluates the evidence supporting use of the tenofovir disoproxil fumarate (TDF) plus lamivudine (3 ​TC) combination as a dual nucleoside backbone within a triple drug antiretroviral regimen. Key trials that assess the relative efficacy, safety and resistance profile of 3 ​TC and emtricitabine (FTC) are discussed. Clinical use of 3 ​TC and FTC with two tenofovir prodrugs -TDF and tenofovir alafenamide (TAF) - is presented. Recommendations from various international guidelines for the construction of triple and emerging dual regimens are summarised. In conclusion, data suggest the therapeutic equivalence of 3 ​TC and FTC, especially when 3 ​TC is combined with TDF.
    Language English
    Publishing date 2021-01-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2868549-0
    ISSN 2055-6659 ; 2055-6640
    ISSN (online) 2055-6659
    ISSN 2055-6640
    DOI 10.1016/j.jve.2021.100028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Pharmacokinetic interactions of modern antiretroviral therapy.

    Sinxadi, Phumla Z / Khoo, Saye H / Boffito, Marta

    AIDS (London, England)

    2021  Volume 35, Issue Suppl 2, Page(s) S145–S151

    Abstract: Drug--drug interactions (DDIs) have been a clinical challenge in HIV medicine for over two decades. The newer antiretroviral drugs (ARTs) have significantly fewer DDIs than protease inhibitors and boosted integrase inhibitors (INSTIs). The lower ... ...

    Abstract Drug--drug interactions (DDIs) have been a clinical challenge in HIV medicine for over two decades. The newer antiretroviral drugs (ARTs) have significantly fewer DDIs than protease inhibitors and boosted integrase inhibitors (INSTIs). The lower propensity of such newer antiretrovirals (e.g. unboosted integrase inhibitors; doravirine) to cause DDIs, has been largely offset by the ageing cohort of patients with multiple comorbidities, who are taking multiple chronic medicines. Furthermore, the introduction of newly marketed drugs into clinical practice needs to be closely monitored, as the new drugs may be perpetrators of DDIs, leading to a potential change in the efficacy or toxicity of the coadministered antiretrovirals.
    MeSH term(s) Anti-HIV Agents/adverse effects ; Anti-Retroviral Agents/adverse effects ; Drug Interactions ; HIV Infections/drug therapy ; Humans ; Integrase Inhibitors
    Chemical Substances Anti-HIV Agents ; Anti-Retroviral Agents ; Integrase Inhibitors
    Language English
    Publishing date 2021-11-29
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 639076-6
    ISSN 1473-5571 ; 0269-9370 ; 1350-2840
    ISSN (online) 1473-5571
    ISSN 0269-9370 ; 1350-2840
    DOI 10.1097/QAD.0000000000002950
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2228: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Ritonavir and COVID-19: pragmatic guidance is important.

    Waters, Laura / Marra, Fiona / Pozniak, Anton / Cockburn, James / Boffito, Marta

    Lancet (London, England)

    2022  Volume 399, Issue 10334, Page(s) 1464–1465

    MeSH term(s) Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; Drug Combinations ; Humans ; Lopinavir/therapeutic use ; Ritonavir/therapeutic use
    Chemical Substances Antiviral Agents ; Drug Combinations ; Lopinavir (2494G1JF75) ; Ritonavir (O3J8G9O825)
    Language English
    Publishing date 2022-03-22
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(22)00280-X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.5: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 94: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative Review.

    Quercia, Romina / Di Perri, Giovanni / Pein, Carolina / Bodie, Jennifer / Singh, Ravi Shankar P / Hendrick, Victoria / Boffito, Marta

    Infectious diseases and therapy

    2024  

    Abstract: Ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme and is commonly used as a pharmacokinetic (PK) enhancer in antiviral therapies because it increases bioavailability of concomitantly administered antivirals. Decades of experience with ... ...

    Abstract Ritonavir is a potent inhibitor of the cytochrome P450 3A4 enzyme and is commonly used as a pharmacokinetic (PK) enhancer in antiviral therapies because it increases bioavailability of concomitantly administered antivirals. Decades of experience with ritonavir-enhanced HIV therapies and, more recently, COVID-19 therapies demonstrate that boosting doses of ritonavir are well tolerated, with an established safety profile. The mechanisms of PK enhancement by ritonavir result in the potential for drug-drug interactions (DDIs) with several classes of drugs, thus making co-medication management an important consideration with enhanced antiviral therapies. However, rates of DDIs with contraindicated medications are low, suggesting these risks are manageable by infectious disease specialists who have experience with the use of PK enhancers. In this review, we provide an overview of ritonavir's mechanisms of action and describe approaches and resources available to mitigate adverse events and manage concomitant medication in both chronic and short-term settings.
    Language English
    Publishing date 2024-04-12
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2701611-0
    ISSN 2193-6382 ; 2193-8229
    ISSN (online) 2193-6382
    ISSN 2193-8229
    DOI 10.1007/s40121-024-00959-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Anastrozole as a therapeutic option for gynecomastia in a person receiving antiretroviral therapy: Case report.

    Senkoro, Elizabeth / Varadarajan, Maithili / Candela, Caterina / Gebreselassie, Abeba / Antoniadi, Christina / Boffito, Marta

    British journal of clinical pharmacology

    2023  Volume 90, Issue 1, Page(s) 350–353

    Abstract: A middle-aged Caucasian man living with HIV, clinically stable (viral load <20 copies/mL) on injectable antiretroviral cabotegravir plus rilpivirine every 2 months presented with a 6-month history of bilateral enlargement of the breasts associated with ... ...

    Abstract A middle-aged Caucasian man living with HIV, clinically stable (viral load <20 copies/mL) on injectable antiretroviral cabotegravir plus rilpivirine every 2 months presented with a 6-month history of bilateral enlargement of the breasts associated with pain. His hormonal profile was normal, and no other underlying cause was identified. He was diagnosed with idiopathic gynecomastia. Tamoxifen is an anti-oestrogen recommended for gynecomastia and has been described in people living with HIV but can potentially induce the activity of cytochrome P450 3A4 (CYP3A4), reducing rilpivirine concentrations, which consequently may cause virological failure and resistance. This is the same for other antiretroviral agents majorly induced by CYP3A4. To date, there have been no reported cases of using anastrozole as a treatment for gynecomastia in people living with HIV or of its co-administration with antiretroviral. We describe the use of an aromatase inhibitor instead of tamoxifen in a person living with HIV, diagnosed with gynecomastia.
    MeSH term(s) Male ; Middle Aged ; Humans ; Anastrozole/therapeutic use ; Gynecomastia/chemically induced ; Gynecomastia/drug therapy ; Cytochrome P-450 CYP3A ; HIV Infections/complications ; HIV Infections/drug therapy ; Rilpivirine/therapeutic use ; Anti-Retroviral Agents/therapeutic use ; Tamoxifen/adverse effects ; Anti-HIV Agents/adverse effects
    Chemical Substances Anastrozole (2Z07MYW1AZ) ; Cytochrome P-450 CYP3A (EC 1.14.14.1) ; Rilpivirine (FI96A8X663) ; Anti-Retroviral Agents ; Tamoxifen (094ZI81Y45) ; Anti-HIV Agents
    Language English
    Publishing date 2023-11-16
    Publishing country England
    Document type Case Reports
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15951
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1118: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top